39549-79-6

Usage

Uses

Used in Organic Synthesis:
2-Amino-4-methylbenzamide serves as a key intermediate in organic synthesis, facilitating the creation of various complex organic molecules. Its unique structure allows it to participate in a range of chemical reactions, making it a valuable component in the synthesis of pharmaceuticals and other specialty chemicals.
Used in Pharmaceutical Research:
In pharmaceutical research, 2-Amino-4-methylbenzamide is utilized as a starting material or a building block for the development of new drugs. Its potential as an inhibitor of protein tyrosine phosphatase 1B positions it as a candidate for the treatment of diabetes and obesity, highlighting its importance in the discovery of novel therapeutic agents.
Used in Industrial Processes:
2-Amino-4-methylbenzamide also finds application in various industrial processes, where its chemical properties are harnessed to improve or enable specific manufacturing techniques. Its versatility in organic synthesis and potential pharmaceutical applications make it a valuable asset in the chemical and pharmaceutical industries.

InChI:InChI=1/C8H10N2O/c1-5-2-3-6(8(10)11)7(9)4-5/h2-4H,9H2,1H3,(H2,10,11)

Upstream product

• 26830-95-5 4-methyl-2-nitrobenzonitrile 
• 26830-96-6 5-methyl-2-cyanoaniline 
• 7647-01-0 hydrogenchloride 
• 65078-05-9 4-methyl-2-nitrobenzamide 
• 1397833-54-3 (2-amino-4-methylphenyl) (benzotriazole-1-yl)methanone 
• 63480-11-5 7-methyl-2H-3,1-benzoxazine-2,4(1H)-dione 
• 2305-36-4 4-methylanthranilic acid 
• 50424-81-2 4-methyl-2-nitro-benzoyl chloride 
• 131002-03-4 4-methyl-2- bromobenzamide 
• 24920-35-2 4-methyl-2-nitrobenzenediazonium 
• 27329-27-7 4-methyl-2-nitrobenzoic acid 

Downstream Products

• 75844-40-5 7-methyl-quinazolin-4(3H)-one 
• 2305-36-4 4-methylanthranilic acid 
• 194473-09-1 2,7-dimethylquinazolin-4(3H)-one 
• 25171-19-1 7-methyl-2,4-dichloroquinazoline 
• 62484-15-5 7-methylquinazoline-2,4-(1H,3H)-dione 
• 1241915-26-3 2-((4-fluorophenyl)(hydroxy)methyl)-7-methylquinazolin-4-ol 
• 1241915-31-0 2-(2,2-difluoro-2-(4-fluorophenyl)acetamido)-4-methylbenzamide 
• 1246861-68-6 2,7-dimethyl-2-phenyl-1,2,3,4-tetrahydro-4-quinazolinone 
• 1319212-79-7 2-(4,6-dichloro-[1,3,5]triazin-2-ylamino)-4-methylbenzamide 
• 1449737-58-9 5-bromo-7-methyl-8-nitro-N-(3-(trifluoromethyl)phenyl)quinazolin-4-amine 
• 943606-89-1 7-methyl-N⁴-(3-(trifluoromethyl)phenyl)quinazoline-4,8-diamine 
• 1093101-62-2 4-(8-(3-(1-(4-methoxybenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)pyridin-2-ylamino)-7-methylquinazolin-4-ylamino)benzonitrile 
• 1093100-20-9 4-(8-(3-(9-(4-methoxybenzyl)-9H-purin-6-yl)pyridin-2-ylamino)-7-methylquinazolin-4-ylamino)benzonitrile 

Relevant academic research and scientific papers

COMBINATION THERAPY FOR TREATING MPS1

The application is directed to compounds of formula (I) and their salts and solvates, wherein B, R1, R2, R3, R3', R4, R4', and R5 are as set forth in the specification, as well as to methods for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and/or prevention of, e.g., MPS1, optionally in combination with α-L-iduronidase or an analog or variant thereof, e.g., laronidase.

Synthesis and nematicidal activities of 1,2,3-benzotriazin-4-one containing 4,5-dihydrothiazole-2-thiol derivatives against Meloidogyne incognita

A series of novel 1,2,3-benzotriazin-4-one derivatives containing 4,5-dihydrothiazole-2-thiol were synthesized and characterized by 1H NMR, 13C NMR, 19F NMR and HRMS. The bioassay results showed that compounds 3-(3-((4,5-dihydrothiazol-2-yl)thio)propyl)-7-methoxybenzo[d][1–3]triazin-4(3H)-one, 3-(3-((4,5-dihydrothiazol-2-yl)thio)propyl)-6-nitrobenzo[d][1–3]triazin-4(3H)-one, 7-chloro-3-(3-((4,5-dihydrothiazol-2-yl)thio)propyl)benzo[d][1–3]triazin-4(3H)-one exhibited good control efficacy against the cucumber root-knot nematode disease caused by Meloidogyne incognita at the concentration of 10.0 mg L?1 in vivo. Compound 7-chloro-3-(3-((4,5-dihydrothiazol-2-yl)thio)propyl)benzo[d][1–3]triazin-4(3H)-one showed excellent nematicidal activity with inhibition 68.3% at a concentration of 1.0 mg L?1. It suggested that the structure of 1,2,3-benzotriazin-4-one containing 4,5-dihydro-thiazole-2-thiol could be optimized further.

Apoptosis signal regulating kinase inhibitor and application thereof

The invention discloses an apoptosis signal regulating kinase inhibitor and an application thereof. The apoptosis signal regulating kinase inhibitor is a compound represented by general formula I, anda tautomer or a pharmaceutically acceptable salt thereo

Substrate Profiling of the Cobalt Nitrile Hydratase from Rhodococcus rhodochrous ATCC BAA 870

The aromatic substrate profile of the cobalt nitrile hydratase from Rhodococcus rhodochrous ATCC BAA 870 was evaluated against a wide range of nitrile containing compounds (>60). To determine the substrate limits of this enzyme, compounds ranging in size from small (90 Da) to large (325 Da) were evaluated. Larger compounds included those with a biaryl axis, prepared by the Suzuki coupling reaction, Morita–Baylis–Hillman adducts, heteroatomlinked diarylpyridines prepared by Buchwald–Hartwig crosscoupling reactions and imidazo[1,2a]pyridines prepared by the Groebke–Blackburn–Bienaymé multicomponent reaction. The enzyme active site was moderately accommodating, accepting almost all of the small aromatic nitriles, the diarylpyridines and most of the biaryl compounds and Morita–Baylis–Hillman products but not the Groebke–Blackburn–Bienaymé products. Nitrile conversion was influenced by steric hindrance around the cyano group, the presence of electron donating groups (e.g., methoxy) on the aromatic ring, and the overall size of the compound.

Trash to treasure: Eco-friendly and practical synthesis of amides by nitriles hydrolysis in WepPA

The hydration of nitriles to amides in a water extract of pomelo peel ash (WEPPA) was realized with moderate to excellent yields without using external transition metals, bases or organic solvents. This reaction features a broad substrate scope, wide functional group tolerance, prominent chemoselectivity, and good reusability. Notably, a magnification experiment in this bio-based solvent at 100 mmol further demonstrated its practicability.

POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS

The present invention is related to a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound represented by the following structural formula: The present invention is also related a method of treating a subject with a disease which can be ameliorated by inhibition of poly(ADP-ribose)polymerase (PARP). The definitions of the variables are provided herein.

On the Synthesis and Reactivity of 2,3-Dihydropyrrolo[1,2- a ]quinazolin-5(1 H)-ones

An improved, scalable synthetic route to the quinazolinone natural product 2,3-dihydropyrrolo[1,2-a]quinazolin-5(1H)-one is reported. The applicability of this method to analogue synthesis and the synthesis of related natural products is explored. Finally, reactivity of the scaffold to a variety of electrophilic reagents, generating products stereoselectively, is reported.

Structure-activity relationships of 2-arylquinazolin-4-ones as highly selective and potent inhibitors of the tankyrases

Tankyrases (TNKSs), members of the PARP (Poly(ADP-ribose)polymerases) superfamily of enzymes, have gained interest as therapeutic drug targets, especially as they are involved in the regulation of Wnt signalling. A series of 2-arylquinazolin-4-ones with varying substituents at the 8-position was synthesised. An 8-methyl group (compared to 8-H, 8-OMe, 8-OH), together with a 4′-hydrophobic or electron-withdrawing group, provided the most potency and selectivity towards TNKSs. Co-crystal structures of selected compounds with TNKS-2 revealed that the protein around the 8-position is more hydrophobic in TNKS-2 compared to PARP-1/2, rationalising the selectivity. The NAD+-binding site contains a hydrophobic cavity which accommodates the 2-aryl group; in TNKS-2, this has a tunnel to the exterior but the cavity is closed in PARP-1. 8-Methyl-2-(4-trifluoromethylphenyl)quinazolin-4-one was identified as a potent and selective inhibitor of TNKSs and Wnt signalling. This compound and analogues could serve as molecular probes to study proliferative signalling and for development of inhibitors of TNKSs as drugs.

THIENO[3,2-D]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES

Provided are a thieno[3,2-d]pyrimidine derivative of formula (I) or a pharmaceutically acceptable salt thereof having inhibitory activity for protein kinase, and a pharmaceutical composition comprising same for prevention and treatment of abnormal cell growth diseases.

BICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS

The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.